The journal Blood has published a six-article series examining the current and future treatment of AML to guide the optimal individual treatment approach. The articles describe the current framework for the clinical management of patients with AML, including emerging therapeutic drugs for AML, targeted epigenetic therapy in AML, the evolving molecular landscape of AML and its clinical relevance, and allogeneic transplantation for patients with AML in first complete remission.
Choose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
AML Review Series in Blood Highlights Latest Advances
Jan 2016